SI-BONE, Inc.

SIBN
About the company

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.

Country: United StatesPrice: $23.44Market Cap: $1.1B

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

8 of 12 pass — Buffett, Lynch, Marks +1 more object

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #1956 (Top 63.2%)NEUTRALFAILFAILFAILFAILFAILPASSFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-24

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-24

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-24

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Buffett, Lynch, Marks +1 more object

    LT Debt vs Net Current AssetsLT Debt $35.7M vs NCA $195.0M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.19, IC: -6.9x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.19
    ✓Lynch< 0.33
    Cash - Long-term Debt$-0.3M
    ✗LynchPositive preferred
    LT Debt / Total Assets Change15.38% -> 14.91%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities7.58
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.19
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.19
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-6.9x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.19
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.1931; #1657/4210 (top 39.4%)
    ✗AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Profitability0% pass✓ 6✗ 29▾

    No clean pass — all 16 investors flag at least one profitability criterion

    Positive EPS (10 years)0/10 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)0/10 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-31.8%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-11.1% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-18.9M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-7.4%
    ✗Lynch> 15%
    EBIT / Enterprise Value-1.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-1.6%, ROC=-9.0%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-7.92%
    ✗PiotroskiROA > 0
    ROA Change YoY-13.41% -> -7.92% (delta: +5.49%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-0.28%, ROA=-7.92%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY79.0% -> 79.6%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-9.5%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-7.4%
    ✗Dreman> 12%
    Margin of SafetyP/B=5.8x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-18.2% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency0/9 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-7.6%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-7.4%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-33.8% (2023) -> -11.1% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 78.8% -> 79.6%, operating margin -33.8% -> -11.1%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-1.29%; #3454/6340 (top 54.5%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+68.23%; #358/3702 (top 9.7%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity-7.41%; #3305/5226 (top 63.2%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1119; #3619/5884 (top 61.5%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years0/9 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation0% pass✓ 1✗ 27▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio5.8x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-1.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-1.6%, ROC=-9.0%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share5.8x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-2.1%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-0.9%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=5.8x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low189% of trailing low ($12.39)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-1.29%; #3454/6340 (top 54.5%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.1746; #4328/6449 (top 67.1%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share5.83x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-22.3%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.2087; #3736/5247 (top 71.2%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-0.40%; #2598/4519 (top 57.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+82.55%; #416/6202 (top 6.7%)
    ✓OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy$-18.9M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-4.2M
    ✗LynchPositive and growing
    Operating Cash Flow$-0.7M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-0.28%, ROA=-7.92%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-0.9%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/9 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-0.4%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/9 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-4.2M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-0.40%; #2598/4519 (top 57.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Verdicts7% pass✓ 1✗ 14▾

    Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #1956•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1365/2370 (Top 57.6%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Growth13% pass✓ 3✗ 10▾

    7 of 8 flag SIBN's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 18.5% vs Rev: 14.0%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction$-6.65 (2017) -> $-0.44 (2025)
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency0/9 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth20.4%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 78.8% -> 79.6%, operating margin -33.8% -> -11.1%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR22.3%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Efficiency38% pass✓ 4✗ 7▾

    5 of 8 flag SIBN's efficiency — Buffett, Greenblatt, Munger +2 more

    Current Ratio7.58
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-25.8%
    ✗Buffett> 10%
    ROIC - WACC-35.8%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-9.0%
    ✗Greenblatt> 25%
    Current Ratio Change YoY7.66 -> 8.55
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.73x -> 0.84x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities7.58
    ✓Dreman> 1.5
    Return on Invested Capital-6.0%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-18.0%; FY2024: ROIC=-13.8%; FY2025: ROIC=-8.3%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -8.3%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Medical Equipment
SIC Sector: Measuring & Medical Instruments
Size: Small Cap($1.1B)
Revenue: $200.9M+20.2% YoY
Net Income: $18.9M+38.8% YoY

Financial Snapshot

Operating Margin-11.1%
Return on Equity-10.6%
Debt / Equity0.20
Current Ratio8.55
EPS (Diluted)$-0.44
Shares Retired−4.0% / −7.6% 2y

Similar Companies

ALCALCON INC
$35.6B
PHGKONINKLIJKE PHILIPS NV
$29.7B
WSTWEST PHARMACEUTICAL SERVICES INC
$29.0B
SNNSMITH & NEPHEW PLC
$13.1B

Shareholder Return

Fiscal 2025

Issued 4.0% of shares last year, 7.6% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-24
FY 2024
Sources
  • 10-K · 2025-02-25
FY 2023
Sources
  • 10-K · 2024-02-27
FY 2022
Sources
  • 10-K · 2023-03-02
FY 2021
Sources
  • 10-K · 2022-03-01
Market Cap$1.1Bcurrent------$732.3Mest.$711.5Mest.$829.9Mest.$595.8Mest.$666.7Mest.
Revenue$220.7M↑14%$55.7M↑14%$56.0M↑15%$52.6M↑11%$200.9M↑20%$167.2M↑20%$138.9M↑31%$106.4M↑18%$90.2M
Operating Income-$16.7M↑34%-$4.4M↑19%-$4.8M↑31%-$5.1M↑32%-$22.3M↑37%-$35.2M↑25%-$46.9M↑21%-$59.6M↓15%-$51.7M
Net Income-$13.7M↑37%-$3.6M↑21%-$4.1M↑34%-$4.3M↑34%-$18.9M↑39%-$30.9M↑29%-$43.3M↑29%-$61.3M↓8%-$56.6M
EPS (Diluted)--$-0.08↑27%$-0.09↑36%$-0.10↑33%$-0.44↑41%$-0.75↑34%$-1.13↑37%$-1.79↓5%$-1.71
Gross Margin79.4%79.3%↓1%79.5%79.8%79.6%↑1%79.0%78.8%↓8%85.2%↓4%88.4%
Operating Margin-7.6%↑42%-7.8%↑29%-8.6%↑40%-9.7%↑39%-11.1%↑47%-21.1%↑38%-33.8%↑40%-56.0%↑2%-57.3%
ROE-7.4%↑41%———-10.6%↑42%-18.5%↑28%-25.6%↑59%-62.3%↓48%-42.1%
Total Debt$35.7M$35.7M$35.6M$35.6M$35.6M$35.5M↓2%$36.1M↑3%$35.2M↑1%$35.0M
Shareholders' Equity$184.7M↑7%$184.7M↑7%$182.3M↑7%$178.9M↑7%$177.5M↑6%$167.0M↓1%$169.4M↑72%$98.3M↓27%$134.4M
Current Ratio7.58↓5%7.58↓5%9.15↑9%9.99↑17%8.55↑12%7.66↓15%9.01↑39%6.50↓38%10.41
Debt / Equity0.19↓6%0.19↓6%0.20↓6%0.20↓6%0.20↓6%0.210.21↓40%0.36↑38%0.26
Operating Cash Flow$6.1M↑597%$5.9M↑154%$777.0K↑349%-$2.4M↑52%-$675.0K↑95%-$12.4M↑34%-$18.7M↑55%-$41.7M↓5%-$39.5M
Free Cash Flow-$4.2M↑60%-$427.0K↑31%-$768.0K↑60%-$3.4M↑51%-$9.1M↑60%-$22.9M↑14%-$26.5M↑48%-$51.2M↓11%-$45.9M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Medical Equipment

SIBN vs Peers — Financial Grading

Revenue$200.9MBottom 25%
Net Income$18.9MBottom 25%
ROE-10.6%Bottom 25%
D/E0.20Top 25%
Op. Margin-11.1%Bottom 25%
Curr. Ratio8.55Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11